

CompuNet

CONNECT

April 2024 / Vol 02 No 04

COMPUNET EXPANDS DIRECT ACCESS TESTING

On April 8, 2024, CompuNet will expand our Direct Access Test menu. With a focus on affordability and accessibility to a variety of patient needs, we're increasing testing options, streamlining with paperless reporting, enhancing reference materials, and have a better utilization of online resources. CompuNet is committed to continually grow this testing menu to adapt to market demand and patient needs.



Scan the QR code or visit compunetlab.com/DAT to see the new, expanded menu of available tests.

ANTI XA ASSAY FOR UNFRACTIONATED HEPARIN (UFH)

Historically the aPTT test was developed as a coagulopathy screening assay; to detect issues such as factor deficiencies, lupus anticoagulants and other inhibitors of the intrinsic coagulation pathway. The aPTT test eventually was used to monitor different anticoagulant drugs such as unfractionated heparin (UFH). However, due to interferences from the above, accurate drug monitoring presents many challenges using the aPTT.

In the past 15 years more accessible and accurate testing has emerged in the laboratory coagulation market - Anti Xa Assay. The Anti Xa assay is a more accurate and direct measurement of the effects of heparin in the patient. Heparin works primarily on Factor Xa and II, thus the Anti Xa assay is more specific for monitoring the anticoagulation effects of heparin.

When compared to traditional aPTT monitoring, Anti Xa assay based UFH monitoring has resulted in achieving therapeutic heparin levels faster, with fewer laboratory tests, and fewer heparin infusion adjustments.^{1,2,3}

Premier Health pharmacy and CompuNet Clinical Laboratory implemented the Anti Xa Assay approximately 4 years ago system wide. The test panel in Epic is called System Heparin Orders Set.

For further questions contact Catherine Hoesl MT(ASCP) System Technical Director Hematology and Coagulation at CompuNet Clinical Laboratory, cchoesl@compunetlab.com

References:

1. Guervil DJ, Rosenberg AF, Winterstein AG, Harris NS, Johns TE, Zumberg MS (2011) Activated partial thromboplastin time versus Anti Factor Xa heparin assay in monitoring unfractionated heparin by continuous intravenous infusion. *Ann Pharmacother* 45:861-868
2. Belk KW, Laposata M, Craver C. A comparison of red blood cell transfusion utilization between anti-activated factor X and activated partial thromboplastin monitoring in patients receiving unfractionated heparin. *J Thromb Haemost*. 2016 Nov;14(11):2148-2157. doi: 10.1111/jth.13476. Epub 2016 Oct 28. PMID: 27543785.
3. Vandiver JW, Vondracek TG. Antifactor Xa levels versus activated partial thromboplastin time for monitoring unfractionated heparin. *Pharmacotherapy*. 2012 Jun;32(6):546-58. doi: 10.1002/j.1875-9114.2011.01049.x. Epub 2012 Apr 24. PMID: 22531940.